George Matcham

Dr. Matcham had 30 successful years at Celgene Corporation, joining in 1988 soon after the IPO when the company had 30 employees, and retiring in 2018 with the company soon to be valued at $74Billion in the acquisition by BMS. During his time at Celgene, he focused mainly on Biotech Research, Development and Manufacturing and held positions such as COO of Celgene Cellular Therapeutics, SVP of Biologics Development and Manufacturing, and SVP CAR T CMC & Technology Development. In these roles, he led internal technical development and clinical manufacturing and was extensively involved in external programs in Biologics and Cell Therapy development, including co-leading CAR T cell manufacturing in the collaboration with Juno, and representing Celgene on the Sutro Biopharma Board of Directors. Before coming to the USA, Dr. Matcham held academic positions in teaching and research at the University of Cambridge and obtained a PhD in Biochemistry at Cardiff University.